CEO Insights: Immunotherapy Innovation, AI Challenges & Clinical Trial Observations

From Auditor to Chairman: A Finance Journey Through Biotech

Our Founder & CEO, Alan Vanderborght, talks with veteran biotech CFO and Chairman of the Board at Egetis Therapeutics, Mats Blom, about a finance-first career across Europe and the US, what AI could mean for drug development, and the personal pull of rare disease - where success is measured in the handful of faces you can actually see.

The Innovator’s Mindset: Evolution in Biotech

In this episode, our Founder & CEO, Alan Vanderborght, sits down with Carter King, EVP Business Development at Protagonist Therapeutics, for a candid conversation about his journey to the frontier of drug development, the science of turning injectables therapies into pills, and the deal-making wisdom and resilience behind a 25-year carreer in biotech.

The Hearing-Dementia Link: Leading a Scientific Revolution

In this episode, our Founder & CEO, Alan Vanderborght, sits down with Celia Beline, CEO of Cilcare, for a conversation about pioneering the field of hearing health, the strategic development of disease-modifying drugs for "hidden" hearing loss, and the critical discovery that hearing is a primary modifiable risk factor for dementia.

Leading a Global Giant: AI Innovation & Microbiome Science

In this episode, Alan sits down with Nicolas Coudurier, CEO of Biocodex, for a conversation on leading a family-owned global giant, the strategic integration of AI, the evolution of microbiome science and its connection to the brain. Nicolas shares insights from his career journey, including what it takes to drive continuous change while successfully scaling across several subsidiaries.

Bridging Science and Capital: Strategic Leadership in Biopharma

In this episode, Alan sits down with David H. Crean,Chief Business Officer at MediciNova, for a conversation on leadership,strategy, and navigating complexity in the biopharma industry. David shares insights from his career journey and whatit takes to build value in late-stage biotech. They explore decision-making inhigh-risk environments, the role of strategic partnerships, and the challengesof advancing innovation in neuroscience today.